ANGLE (OTCMKTS:ANPCY) vs. Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey

Adaptive Biotechnologies (NASDAQ:ADPT) and ANGLE (OTCMKTS:ANPCY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares Adaptive Biotechnologies and ANGLE”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98 million	15.13	-$59.50 million	($0.41)	-64.02
ANGLE	N/A	N/A	N/A	C($0.48)	-0.14

ANGLE has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adaptive Biotechnologies and ANGLE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
ANGLE	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Adaptive Biotechnologies and ANGLE, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1	1	5	0	2.57
ANGLE	0	0	0	0	0.00

Adaptive Biotechnologies presently has a consensus price target of $24.42, suggesting a potential downside of 6.98%. Given Adaptive Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than ANGLE.

Insider and Institutional Ownership

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Adaptive Biotechnologies beats ANGLE on 7 of the 11 factors compared between the two stocks.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.